Chemotherapy Induced Neutropenia – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia – Pipeline Review, H2 2019’, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia

– The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“BeyondSpring Inc

Biocon Ltd

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Dr. Reddy’s Laboratories Ltd

Enzychem Lifesciences Corp

Gene Techno Science Co Ltd

Generon (Shanghai) Corp Ltd

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

Lupin Ltd

Mycenax Biotech Inc

Nohla Therapeutics Inc

Pangen Biotech Inc

Pfizer Inc

PharmaEssentia Corp

Profarma

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Tanvex BioPharma Inc

USV Pvt Ltd

Valenta Pharm”

Table of Contents

Table of Contents

Introduction

Chemotherapy Induced Neutropenia Overview

Chemotherapy Induced Neutropenia Therapeutics Development

Chemotherapy Induced Neutropenia Therapeutics Assessment

Chemotherapy Induced Neutropenia Companies Involved in Therapeutics Development

Chemotherapy Induced Neutropenia Drug Profiles

Chemotherapy Induced Neutropenia Dormant Projects

Chemotherapy Induced Neutropenia Discontinued Products

Chemotherapy Induced Neutropenia Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by BeyondSpring Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Biocon Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Bolder Biotechnology Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Cellerant Therapeutics Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Dr. Reddy’s Laboratories Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Enzychem Lifesciences Corp, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Gene Techno Science Co Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Generon (Shanghai) Corp Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by GlycoMimetics Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Lupin Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Mycenax Biotech Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Nohla Therapeutics Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Pangen Biotech Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Pfizer Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by PharmaEssentia Corp, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Profarma, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Richter Gedeon Nyrt, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Tanvex BioPharma Inc, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by USV Pvt Ltd, H2 2019

Chemotherapy Induced Neutropenia – Pipeline by Valenta Pharm, H2 2019

Chemotherapy Induced Neutropenia – Dormant Projects, H2 2019

Chemotherapy Induced Neutropenia – Dormant Projects, H2 2019 (Contd..1), H2 2019

Chemotherapy Induced Neutropenia – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports